Gene · 2921
NIH grants2,607
NIH grants whose papers are about the gene, through NIH's grant-paper links.
301 to 320 of 2,607
Download this page as JSON| Grant | Title | CXCL3 papers | Newest fiscal year |
|---|---|---|---|
| R01CA254036 | Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer | 1 | 2025 |
| R01CA254104 | Investigating Macrophage Molecular and Functional Diversity in Tumor Immunity | 1 | 2025 |
| R01CA257861 | Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis | 1 | 2025 |
| R01CA258523 | Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer | 1 | 2025 |
| R01CA258886 | Macrophages as modulators of T cell function and therapeutic response in clear cell renal cell carcinoma | 1 | 2025 |
| R01CA259001 | Targeting mechanisms of immune evasion in chemotherapy-induced senescent cells | 1 | 2025 |
| R01CA260449 | Exploiting gold nanoparticle as a probe to identify therapeutic targets | 1 | 2025 |
| R01CA262188 | Development of a generalizable chemo-proteomics screening platform for small molecule degraders applied to HDACs | 1 | 2025 |
| R01CA262430 | Control of regulatory T cells by IL-17 in colorectal cancer | 1 | 2025 |
| R01CA262822 | Role of type 2 immune response in pancreatic cancer tumorigenesis | 1 | 2025 |
| R01CA269811 | Deploying Histotripsy Based Tumor Ablation Strategies to Treat Pancreatic Cancer | 1 | 2025 |
| R01CA272875 | The Role of Cancer-Associated Fibroblasts in Thyroid Carcinoma | 1 | 2025 |
| R01CA274439 | Optimization of High Frequency Irreversible Electroporation (H-FIRE) for tumor ablation and immune system activation in pancreatic cancer applications | 1 | 2025 |
| R01CA274605 | Leveraging PMN immune response to overcome ADT resistance in bone metastatic prostate cancer | 1 | 2025 |
| R01CA276279 | The Role of Egfl6 in Tumor Immunity | 1 | 2025 |
| R01DE012505 | Molecular Aspects of Oral Plaque Formation | 1 | 2025 |
| R01DE025141 | Developing new therapeutic strategies against head and neck cancer | 1 | 2025 |
| R01DE030875 | Functional roles of GOF TP53 mutations in metastasis and immunosuppression of head and neck cancers | 1 | 2025 |
| R01DE031928 | Initiation of immune responses to SARS COV2 in the oral cavity and upper airway | 1 | 2025 |
| R01DK032083 | Multiple Autoantigens, Multiple Epitopes of Type 1 Diabetes | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2921/grants?page=16